enGene Therapeutics Inc. (ENGNW)Montreal, Canada | NasdaqCM
0.32 USD
+0.03
(10.345%)
⇧
(July 13, 2026, 10:51 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:40 a.m. EDT
The security is trapped in a dead zone where the fundamental reality of massive losses and negative cash flow clashes violently with a statistical model screaming for a massive short-term pop. The price history shows a flat line at $2.23, indicating zero momentum and no trading interest, while the fundamentals reveal a company burning through cash with negative operating and free cash flows, alongside significant debt relative to equity. The statistical forecast suggests a 237% move, but with such low reliability and wide confidence intervals, this is likely noise rather than a tradeable signal. Without a clear path to profitability or a catalyst to revive demand, the business quality appears deteriorated, making it a poor candidate for either a quick trade or a long-term hold. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.000000 |
| AutoETS | 0.000149 |
| MSTL | 0.002171 |
| AutoTheta | 0.022454 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.00 |
| Ljung-Box p | nan |
| Jarque-Bera p | nan |
| Excess Kurtosis | nan |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 13.07 |
| Beta | -0.28 |
| Previous Name | enGene Holdings Inc. |
| Website | https://www.engene.com |
| Attribute | Value |
|---|---|
| Address1 | 4,868 Rue Levy |
| Address2 | Suite 220 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | -0.275 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 3.809 |
| City | Montreal |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.32 |
| Current Ratio | 12.567 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.32 |
| Day Low | 0.32 |
| Debt To Equity | 13.07 |
| Display Name | enGene Therapeutics |
| Ebitda | -131,911,000 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.32 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.32 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.32 - 0.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 22,487,024 |
| Free Cashflow | -69,263,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,023-11-01 |
| Language | en-US |
| Long Business Summary | enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada. |
| Long Name | enGene Therapeutics Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_9516520 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -126,850,000 |
| Open | 2.1 |
| Operating Cashflow | -109,997,000 |
| Operating Margins | 0.0 |
| Phone | 514 332 4888 |
| Prev Name | enGene Holdings Inc. |
| Previous Close | 0.29 |
| Price Hint | 4 |
| Price To Book | 0.08401155 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.166 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.030000001 |
| Regular Market Change Percent | 10.344829 |
| Regular Market Day High | 0.32 |
| Regular Market Day Low | 0.32 |
| Regular Market Day Range | 0.32 - 0.32 |
| Regular Market Open | 2.1 |
| Regular Market Previous Close | 0.29 |
| Regular Market Price | 0.32 |
| Regular Market Time | 1,783,954,291 |
| Regular Market Volume | 2,000 |
| Return On Assets | -0.28863 |
| Return On Equity | -0.52585 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | enGene Holdings Inc. Warrants |
| Source Interval | 15 |
| State | QC |
| Symbol | ENGNW |
| Total Cash | 258,464,992 |
| Total Cash Per Share | 3.858 |
| Total Debt | 33,351,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 2,000 |
| Website | https://www.engene.com |
| Zip | H4R 2P1 |